Genomic Valley Biotech (BOM:539206) Cyclically Adjusted PB Ratio: (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539206 Genomic Valley Biotech Ltd BOM:539206
62 GF Score
Price ₹31.50
GF Value ₹11.18
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Genomic Valley Biotech Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Genomic Valley Biotech  (BOM:539206) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genomic Valley Biotech Cyclically Adjusted PB Ratio Related Terms


Genomic Valley Biotech Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Genomic Valley Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomic Valley Biotech Cyclically Adjusted PB Ratio Chart

Genomic Valley Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.35 1.64

Genomic Valley Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.87 0.00 1.64 0.00

BOM:539206 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Genomic Valley Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomic Valley Biotech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genomic Valley Biotech's Cyclically Adjusted PB Ratio falls into.


BOM:539206
62GF Score
Genomic Valley Biotech Ltd BOM:539206
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomic Valley Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genomic Valley Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Genomic Valley Biotech's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Genomic Valley Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201609 14.755 105.961 23.304
201612 0.000 105.196 0.000
201703 14.712 105.196 23.405
201706 0.000 107.109 0.000
201709 14.731 109.021 22.613
201712 0.000 109.404 0.000
201803 14.823 109.786 22.596
201806 0.000 111.317 0.000
201809 14.878 115.142 21.625
201812 0.000 115.142 0.000
201903 15.584 118.202 22.065
201906 0.000 120.880 0.000
201909 15.693 123.175 21.322
201912 0.000 126.235 0.000
202003 16.520 124.705 22.170
202006 0.000 127.000 0.000
202009 15.991 130.118 20.568
202012 0.000 130.889 0.000
202103 14.691 131.771 18.659
202106 0.000 134.084 0.000
202109 10.710 135.847 13.194
202112 0.000 138.161 0.000
202203 9.423 138.822 11.360
202206 0.000 142.347 0.000
202209 11.127 144.661 12.873
202212 0.000 145.763 0.000
202303 11.545 146.865 13.156
202306 0.000 150.280 0.000
202309 11.708 151.492 12.934
202312 0.000 152.924 0.000
202403 11.594 153.035 12.679
202406 0.000 155.789 0.000
202409 12.495 157.882 13.245
202412 0.000 158.323 0.000
202503 12.760 157.552 13.554
202506 0.000 159.755 0.000
202509 12.851 162.289 13.252
202512 0.000 163.281 0.000
202603 12.859 164.272 13.100
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?

Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued. The current stock price of ₹31.50 is trading 181.8% above its estimated GF Value™ of ₹11.18. GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.

Key valuation signals for BOM:539206:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹11.18 vs. price of ₹31.50 (181.8% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomic Valley Biotech Business Description

Address 4 K.M. Stone, Berri Charra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, Village Kherka Musalman, Jhajjar, HR, IND, 124507
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
62GF Score

Get the complete analysis for BOM:539206

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹31.50
Price
₹11.18
GF Value